Skip to Content
Merck
CN

SML0223

Zoledronic acid monohydrate

≥98% (HPLC), FPP synthase inhibitor, powder

Synonym(s):

P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate, Zoledronate monohydrate, [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C5H10N2O7P2·H2O
CAS Number:
165800-06-6
Molecular Weight:
290.10
UNSPSC Code:
12352204
PubChem Substance ID:
329825242
NACRES:
NA.77
MDL number:
MFCD08448695

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Zoledronic acid monohydrate, ≥98% (HPLC)

SMILES string

O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O

InChI key

FUXFIVRTGHOMSO-UHFFFAOYSA-N

InChI

1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2

assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

color

white to beige

solubility

H2O: ≥2 mg/mL

storage temp.

2-8°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Zoledronic acid monohydrate has been used:
  • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4
  • as a conjugate with D,L-lactide 75: glycolide 25 (PLGA) to analyze its bone formation functionality in distal femur
  • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells

Biochem/physiol Actions

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.
Zoledronic acid (zoledronate) is a bone resorption inhibitor, an inhibitor of farnesyl diphosphate synthase

Preparation Note

This product is extremely unstable in solution and should be used shortly after reconstitution. If storage of the solution is necessary it can be held at 2-8ºC for no more than 24 hours.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000485245
0000485246
0000485246
0000485245
0000368339

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ramez H Mahmoud et al.
Scientific reports, 11(1), 19535-19535 (2021-10-03)
This study investigated the role 5-lypoxigenase (5-LO) on alveolar socket healing in aged female mice treated with zoledronic acid (ZL). Forty 129/Sv female mice (64-68 weeks old), 20 wild type (WT) and 20 5-LO knockout (5LOKO) were equally distributed according to
Claudia B Colon-Echevarria et al.
Cancers, 12(9) (2020-09-24)
Multiple studies suggest that chronic stress accelerates the growth of existing tumors by activating the sympathetic nervous system. Data suggest that sustained adrenergic signaling can induce tumor growth, secretion of pro-inflammatory cytokines, and macrophage infiltration. Our goal was to study
Controlled delivery of zoledronate improved bone formation locally in vivo
Gou W, et al.
PLoS ONE, 9(3), e91317-e91317 (2014)
Xu Li et al.
International journal of pharmaceutics, 526(1-2), 69-76 (2017-04-30)
Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce
Xu Li et al.
ACS applied materials & interfaces, 11(7), 7311-7319 (2019-01-29)
Bisphosphonates are generally used to treat bone diseases, such as bone metastasis from cancer. There is evidence that, through the modification of the pharmacokinetics and biodistribution of bisphosphonates by formulating them into nanoparticles, they may be able to treat extraskeletal
View All Related Papers

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service